LOS ANGELES, Aug. 26 (Xinhua) — U.S. pharmaceutical company Lilly announced Tuesday that its experimental oral GLP-1 receptor agonist, orforglipron, achieved positive results in a Phase 3 trial targeting adults with overweight and type 2 diabetes.
In the trial, participants receiving the highest dose of orforglipron over 72 weeks lost an average of 22.9 pounds (around 10.3 kilograms), about 10.5 percent of their body weight, a meaningful reduction for a population that typically faces greater challenges in losing weight, the company said in a statement.
The treatment also lowered A1C (amounts of sugar in blood) levels by up to 1.8 percent and improved multiple cardiometabolic risk factors, according to the company.
GLP-1, a natural appetite- and blood sugar-regulating hormone, is the target of diabetes and weight-loss drugs that replicate its effects.
With completion of the trial, the company said it now has the full clinical data required to initiate global regulatory submissions for the drug.
The most common side effects are gastrointestinal-related and generally mild-to-moderate in severity, according to the company.
